Table of Contents
Table of Exhibits
Executive Summary
- 2006-2011 Market Dynamics
- Competitive Landscape
- Brand Overview
- Physician Perspectives
Section 1: Introduction
- Report Scope
- Survey Methodology
Section 2: Disease Dynamics
- Disease Background
- Incidence and Drug Treatable Pool
- Major Markets Statistics and Key Findings
- US Statistics and Key Findings
- Europe Statistics and Key Findings
- Japan Statistics and Key Findings
- Prescribers
- Prescriber Trends
- Physician Perceptions of Unmet Needs in CRC
- Key Drivers of Prescriber Decisions
- Reimbursement Issues
- Treatment Dynamics
- Stage I
- Stage II
- Stage III
- Stage IV
- Existing Therapies
- Emerging Therapies
Section 3: Competitive Analysis
- Overview of Competitive Landscape
- Promotional Spending
- Brand Overview
- CRC Market Messaging
- Physician Perceptions
- Perceptions of Competitors in CRC
- Perceptions of Brands in CRC
Section 4: Established Competitors
- Roche/Genentech
- Strategic Overview
- Oncology Product Portfolio
- Goals and Vision in Oncology
- Current Positioning
- Market Strategy
- Outlook
- Avastin
- Current Positioning
- Avastin Competitive Analysis
- Key Brand Strategies
- Future Positioning and Outlook
- Xeloda
- Current Positioning
- Xeloda Competitive Analysis
- Key Brand Strategies
- Future Positioning and Outlook
- Sanofi-Aventis
- Strategic Overview
- Oncology Product Portfolio
- Goals and Vision in Oncology
- Current Positioning
- Physician Perception
- Market Strategy
- Outlook
- Eloxatin
- Current Positioning
- Eloxatin Competitive Analysis
- Key Brand Strategies
- Future Positioning and Outlook
- Pfizer
- Strategic Overview
- Oncology Product Portfolio
- Goals and Vision in CRC
- Current Positioning
- Market Strategy
- Outlook
- Camptosar
- Current Positioning
- Camptosar Competitive Analysis
- Key Brand Strategies
- Future Positioning and Outlook
- Sutent
- Development and Commercial Overview
- Future Positioning and Outlook
- BMS/ImClone
- Strategic Overview
- Oncology Product Portfolio
- Goals and Vision in Oncology
- Current Positioning
- Market Strategy
- Outlook
- Erbitux
- Current Positioning
- Erbitux Competitive Analysis
- Key Brand Strategies
- Future Positioning and Outlook
- Amgen
- Strategic Overview
- Oncology Product Portfolio
- Goals and Vision in Oncology
- Current Positioning
- Market Strategy
- Outlook
- Vectibix
- Current Positioning
- Vectibix Competitive Analysis
- Key Brand Strategies
- Future Positioning and Outlook
Section 5: Emerging Competitors
- AstraZeneca
- Strategic Overview
- Oncology Product Portfolio
- Goals and Vision in Oncology
- Outlook
- Recentin
- Development and Commercial Overview
- Future Positioning
Section 6: Market Forecast
- CRC Market Analysis
- Sales by Region
- Sales by Brand
- Sales by Company
Section 7: Appendices
- Acronyms and Abbreviations
- Methodology
- Epidemiology
- Market Forecast
- Competitive Analysis
Table of Exhibits
Executive Summary
- Exhibit 1: Key Parameters of the CRC Market
- Exhibit 2: CRC Branded Market, Major Markets, 2006-2011
- Exhibit 3: CRC Market Competitive Position, 2006 and 2011
- Exhibit 4: Leading CRC Brand Sales, 2006 and 2011
- Exhibit 5: Physician-Ranked "Best" Companies in the CRC Market
- Exhibit 6: Top-of-Mind Brands in CRC Treatment
Section 1: Introduction
- Exhibit 7: Surveyed Physicians' Years of Practice
- Exhibit 8: Surveyed Physicians' CRC Patients per Month
- Exhibit 9: Surveyed Physicians' Geographic Distribution
Section 2: Disease Dynamics
- Exhibit 10: Colorectal Anatomy
- Exhibit 11: Drug Treatable and Incident CRC Cases, Major Markets
- Exhibit 12: Incident CRC cases, by Stage, Major Markets, 2006-2011
- Exhibit 13: Incident CRC Cases, by Stage, as Percentage of Total, Major
Markets, 2006
- Exhibit 14: Drug Treatable and Incident CRC Cases, United States
- Exhibit 15: Drug Treatable and Incident CRC Cases, Europe
- Exhibit 16: Drug Treatable CRC Cases, by Country, Europe, 2006-2011
- Exhibit 17: Incident CRC Cases by Stage, as a Percentage of Total, Europe,
2006
- Exhibit 18: Drug Treatable and Incident CRC Cases, Japan
- Exhibit 19: Physician Perceptions of Unmet Needs in CRC
- Exhibit 20: Importance to CRC Treatment of Resolution for Unmet Needs
- Exhibit 21: Top Factors Influencing Treatment Decisions in Non-Medicare
Versus Medicare CRC Patients
- Exhibit 22: Preferred Information Sources for CRC Physicians
- Exhibit 23: Influence of Information Sources for Emerging Therapies
- Exhibit 24: US Formulary Status of Select CRC Drugs
- Exhibit 25: Percentage of US Private Plans Listing Avastin, Erbitux, or
Sutent as Medical Benefit, Pharmacy Benefit, or Off Formulary
- Exhibit 26: Percentage of Medicare PDP Plans Listing Avastin, Erbitux, or
Sutent as Medical Benefit, Pharmacy Benefit, or Off Formulary
- Exhibit 27: Coinsurance Requirements of US Private Plans for Avastin,
Erbitux, and Sutent
- Exhibit 28: Coinsurance Requirements of US Medicare Plans for Avastin,
Erbitux, and Sutent
- Exhibit 29: Treatment Algorithm for Stage I CRC
- Exhibit 30: Treatment Algorithm for Stage II CRC
- Exhibit 31: Treatment Algorithm for Stage III CRC
- Exhibit 32: Treatment Algorithm for Stage IV CRC
- Exhibit 33: Existing CRC Drugs
- Exhibit 34: Existing CRC Regimens
- Exhibit 35: Emerging CRC Drugs
Section 3: Competitive Analysis
- Exhibit 36: CRC Sales ($US), by Country, 2006
- Exhibit 37: Leading Brands in the CRC Market, 2006
- Exhibit 38: CRC Market Competitive Position, 2006 and 2011
- Exhibit 39: CRC Market ($US), by Company, 2006-2011
- Exhibit 40: Promotional Spend by Company, as a % of Total, 2006
- Exhibit 41: Promotional Spend, by Brand, as a % of Total, 2004-2006
- Exhibit 42: Volume of Promotional Material Received by Physicians, by Brand
- Exhibit 43: Promotional Spend, by Brand, by Category, 2006
- Exhibit 44: Labeled Indications for Key Brands, 2006
- Exhibit 45: Current Price per Cycle ($), Key Brands, 2006
- Exhibit 46: Physician Perception of Most Influential Messaging in the CRC
Market
- Exhibit 47: Physician Perception of Most Influential Branded-Drug
Messaging in the CRC Market
- Exhibit 48: Physician Perception of Most Influential Company Messaging in
the CRC Market
- Exhibit 49: Top-of-Mind Companies in the CRC Market
- Exhibit 50: Importance of Various Factors to Physician Perception of CRC
Competitors
- Exhibit 51: Physician Perception of the Reputations of CRC Competitors
- Exhibit 52: Physician-Ranked "Best" Companies in the CRC Market
- Exhibit 53: Top-of-Mind Brands in CRC Treatment
- Exhibit 54: Most Influential Factors for Choosing a Specific CRC Therapy
Section 4: Established Competitors
- Exhibit 55: Summary of Roche/Genentech' s Oncology Product Portfolio
- Exhibit 56: Physician Perceptions of the Roche and Genentech Relationship
- Exhibit 57: Physician Perceptions of Genentech in CRC
- Exhibit 58: Physician Perceptions of Roche in CRC
- Exhibit 59: Physician Perceptions of Avastin
- Exhibit 60: Ongoing Clinical Trials for Avastin
- Exhibit 61: Avastin Sales ($US), 2006-2011
- Exhibit 62: Avastin Sales ($US), by Country, 2006-2011
- Exhibit 63: Physician Perceptions of Xeloda
- Exhibit 64: Ongoing Clinical Trials for Xeloda
- Exhibit 65: Xeloda Sales ($US), 2006-2011
- Exhibit 66: Xeloda Sales ($US), by Country, 2006-2011
- Exhibit 67: Summary of Sanofi-Aventis' s Oncology Product Portfolio
- Exhibit 68: Physician Perception of Sanofi-Aventis in CRC
- Exhibit 69: Physician Perceptions of Eloxatin
- Exhibit 70: Ongoing Clinical Trials for Eloxatin
- Exhibit 71: Eloxatin Sales ($US), 2006-2011
- Exhibit 72: Eloxatin Sales ($US), by Country, 2006-2011
- Exhibit 73: Summary of Pfizer' s Oncology Product Portfolio
- Exhibit 74: Physician Perceptions of Pfizer in CRC
- Exhibit 75: Physician Perceptions of Camptosar
- Exhibit 76: Ongoing Clinical Trials for Camptosar (continued on next page)
- Exhibit 77: Camptosar Sales ($US), 2006-2011
- Exhibit 78: Camptosar Sales ($US), by Country, 2006-2011
- Exhibit 79: Expected Sutent Sales ($US), by Country, 2011
- Exhibit 80: Summary of BMS' s Oncology Product Portfolio
- Exhibit 81: Physician Perceptions of BMS in CRC
- Exhibit 82: Physician Perceptions of ImClone in CRC
- Exhibit 83: Physician Perceptions of Erbitux
- Exhibit 84: Ongoing Clinical Trials for Erbitux (continued on next two
pages)
- Exhibit 85: Erbitux Sales ($US), 2006-2011
- Exhibit 86: Erbitux Sales ($US), by Country, 2006-2011
- Exhibit 87: Summary of Amgen' s Oncology Product Portfolio
- Exhibit 88: Physician Perceptions of Amgen in CRC
- Exhibit 89: Physician Perceptions of Vectibix
- Exhibit 90: Ongoing Clinical Trials for Vectibix
- Exhibit 91: Vectibix Revenue ($US), 2006-2011
- Exhibit 92: Vectibix Revenue ($US), by Country, 2006-2011
Section 5: Emerging Competitors
- Exhibit 93: Summary of AstraZeneca' s Oncology Product Portfolio
- Exhibit 94: Expected Recentin Revenue ($US), by Country, 2011
Section 6: Market Forecast
- Exhibit 95: CRC Market ($US), Major Markets, 2006-2011 (Tabular Format)
- Exhibit 96: CRC Market ($US), Major Markets, 2006-2011 (Graphical Format)
- Exhibit 97: Timeline of Key Events, CRC Market, 2006-2011
- Exhibit 98: CRC Market ($US), by Country, 2006-2011
- Exhibit 99: CRC Market ($US), by Brand, 2006-2011
- Exhibit 100: CRC Market ($US), by Company, 2006-2011
Section 7: Appendices
- Exhibit 101: Discount Rates
- Exhibit 102: Dosing Assumptions for CRC Regimens
|
Related Report
|
View Cart
